Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Overview of attention for article published in Journal of Hematology & Oncology, February 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 3 news outlets

Citations

dimensions_citation: 57 Dimensions

Readers on

mendeley: 47 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Moxetumomab Pasudotox Will Be Removed From US Market for Hairy Cell Leukemia

Oncology Nursing News, 17 Jan 2023

AstraZeneca has announced that they will be permanently discontinuing Moxetumomab pasudotox-tdfk (Lumoxiti) for the treatment…

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

OncLive, 13 Jan 2023

Hairy Cell Leukemia (Kateryna_Kon - stock.adobe.com) Moxetumomab pasudotox-tdfk (Lumoxiti) will be permanently discontinued in…

Moxetumomab Pasudotox Shows Durable Responses for Patients With Relapsed/Refractory Hairy Cell Leukemia

Cancer Therapy Advisor, 01 Apr 2021

Long-term follow-up results of a pivotal trial involving moxetumomab pasudotox indicated durable responses for patients with…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.